Anavex Life Sciences Corp (AVXL)

[stealthways]

There are no reasonable comparables within the CNS space, in terms of value, to the indications avxl is treating.... That is why when I was looking for a comparable I looked outside CNS and into the Hep C indication....The lead drug there was bought out in 2011 for 10.4 B ... this was before it was approved, and with a much smaller market than where avxl is developing in CNS (but it is likely the closest (but still much smaller) size , amongst recent unapproved drug sales, to potential comparison I can find)... There is a big effort IMO to pound avxl shareholders into some kind of submission into thinking an insanely low value is justified...